Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors

Haematologica

Volumn 101, Issue 12, 2016, Pages 1499-1507

  Baschant, Ulrike ^a   Rauner, Martina ^a   Balaian, Ekaterina ^a   Weidner, Heike ^a   Roetto, Antonella ^b   Platzbecker, Uwe ^a   Hofbauer, Lorenz C ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DEFEROXAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; WNT5A PROTEIN; IRON; IRON CHELATING AGENT; TRANSCRIPTION FACTOR NFAT;

ADULT; ANIMAL CELL; ARTICLE; BONE MARROW STROMA CELL; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; HEMOCHROMATOSIS; HUMAN; HUMAN CELL; IRON CHELATION; IRON DEFICIENCY; IRON OVERLOAD; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; OSTEOBLAST; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; BONE DEVELOPMENT; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; YOUNG ADULT;

ADULT; ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; DEFEROXAMINE; GENE EXPRESSION REGULATION; HUMANS; IRON; IRON CHELATING AGENTS; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; WNT-5A PROTEIN; YOUNG ADULT;

EID: 85002251295     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.144808     Document Type: Article

References (53)

1. Cassat JE & Skaar EP. Iron in infection and immunity. Cell Host Microbe. 2013;13(5):509-520.
2. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117(3):285-297.
3. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013;65:1174-1194.
4. Abraham R, Walton J, Russell L, et al. Dietary determinants of post-menopausal bone loss at the lumbar spine: a possible beneficial effect of iron. Osteoporos Int. 2006;17(8):1165-1173.
5. Harris MM, Houtkooper LB, Stanford VA, et al. Dietary iron is associated with bone mineral density in healthy postmenopausal women. J Nutr. 2003;133(11):3598-3602.
6. Katsumata S, Katsumata-Tsuboi R, Uehara M, Suzuki K. Severe iron deficiency decreases both bone formation and bone resorption in rats. J Nutr. 2009;139(2):238-243.
7. Medeiros DM, Plattner A, Jennings D, Stoecker B. Bone morphology, strength and density are compromised in iron-deficient rats and exacerbated by calcium restriction. J Nutr. 2002;132(10):3135-3141.
8. Kenner GH, Brik AB, Liu G, et al. Variation of long-lived free radicals responsible for the EPR native signal in bone of aged or diseased human females and ovariectomized adult rats. Radiat Meas. 2005; 39(3):255-262.
9. Liu G, Men P, Kenner GH, Miller SC. Ageassociated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals. 2006;19(3):245-251.
10. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16(12):1809-1814.
11. Skordis N, Toumba M. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. Pediatr Endocrinol Rev. 2011;Suppl 2:300-306.
12. Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R. Bone mass density in adults with sickle cell disease. Br J Haematol. 2007;136(4):666-672.
13. Valenti L, Varenna M, Fracanzani AL, et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009; 20(4):549-555.
14. Casale M, Citarella S, Filosa A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with α-thalassemia major. Am J Hematol. 2014;89(12):1102-1106.
15. Isomura H, Fujie K, Shibata K, et al. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology. 2004;15:197(2):93-100.
16. Kudo H, Suzuki S, Watanabe A, et al. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology. 2008;246(2-3):143-147.
17. Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood. 2010;116(14):2582-2589.
18. Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med. 2009; 15(3):259-266.
19. Jia P, Xu YJ, Zhang ZL, et al. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res. 2012;30(11):1843-1852.
20. Xiao W, Beibei F, Guangsi S, et al. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol. 2015;226(3):121-134.
21. Xie W, Lorenz S, Dolder S, Hofstetter W. Extracellular iron is a modulator of the differentiation of osteoclast lineage cells. Calcif Tissue Int. 2016;98(3):275-283.
22. Guo JP, Pan JX, Xiong L, et al. Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease. PLoS One. 2015;10(11):e0139395.
23. Doyard M, Fatih N, Monnier A, et al. Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. Osteoporos Int. 2012;23(10):2435-2445.
24. Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol Lett. 2009;191(2-3):211-215.
25. Messer JG, Kilbarger AK, Erikson KM, Kipp DE. Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone. 2009;45(5):972-979.
26. Chung JH, Kim YS, Noh K, et al. Deferoxamine promotes osteoblastic differentiation in human periodontal ligament cells via the nuclear factor erythroid 2-related factor-mediated antioxidant signaling pathway. J Periodontal Res. 2014;49(5):563-573.
27. Qu ZH, Zhang XL, Tang TT, Dai KR. Promotion of osteogenesis through betacatenin signaling by desferrioxamine. Biochem Biophys Res Commun. 2008;370(2):332-337.
28. Zhao GY, Zhao LP, He YF, et al. A comparison of the biological activities of human osteoblast hFOB1. 19 between iron excess and iron deficiency. Biol Trace Elem Res. 2012;150(1-3):487-495.
29. Farberg AS, Jing XL, Monson LA, et al. Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Bone. 2012;50(5):1184-1187.
30. Wan C, Gilbert SR, Wang Y, et al. Role of hypoxia inducible factor-1 alpha pathway in bone regeneration. J Musculoskelet Neuronal Interact. 2008;8(4):323-324.
31. Messer JG, Cooney PT, Kipp DE. Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells. Bone. 2010;46(5):1408-1415.
32. Baron R & Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179-192.
33. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107(4):513-523.
34. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblastlineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012;18(3):405-412.
35. Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, and Stappenbeck TS. Wnt5a potentiates TGF-beta signaling to promote colonic crypt regeneration after tissue injury. Science. 2012;338(6103):108-113.
36. Roetto A, Di Cunto F, Pellegrino RM, et al. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. Blood. 2010;115(16):3382-3389.
37. Rauner M, Föger-Samwald U, Kurz MF, et al. Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone. 2014;64:281-287.
38. Sinningen K, Albus E, Thiele S, et al. Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis. Bone. 2015;76(25):107-114.
39. Rauner M, Stein N, Winzer M, et al. WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res. 2012;27(3):575-585.
40. Alvarez-Tejado M, Naranjo-Suarez S, Jiménez C, et al. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem. 2001;276(25):22368-22374.
41. Huang C, Li J, Zhang Q, Huang X. Role of bioavailable iron in coal dust-induced activation of activator protein-1 and nuclear factor of activated T cells: difference between Pennsylvania and Utah coal dusts. Am J Respir Cell Mol Biol. 2002;27(5):568-574.
42. Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Cutan Ocul Toxicol 2010;29(2):122-129.
43. Markel TA, Crisostomo PR, Wang M, et al. Iron chelation acutely stimulates fetal human intestinal cell production of IL-6 and VEGF while decreasing HGF: the roles of p38, ERK, and JNK MAPK signaling. Am J Physiol Gastrointest Liver Physiol. 2007; 292(4):958-963.
44. Chen B, Yan YL, Liu C, et al. Therapeutic effect of deferoxamine on iron overloadinduced inhibition of osteogenesis in a zebrafish model. Calcif Tissue Int. 2014; 94(3):353-360.
45. Naves Díaz ML, Elorriaga R, Canteros A, Cannata Andía JB. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity. Nephrol Dial Transplant. 1998;Suppl 3:23-28.
46. Chen D, Li Y, Zhou Z, et al. Synergistic inhibition of Wnt pathway by HIF-1α and osteoblast-specific transcription factor osterix (Osx) in osteoblasts. PLoS One. 2012;7(12):e52948.
47. Meng H, Li F, Hu R, et al. Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition. Brain Res. 2015;1602:44-52.
48. Ziaei A, Ardakani MR, Hashemi MS, et al. Acute course of deferoxamine promoted neuronal differentiation of neural progenitor cells through suppression of Wnt/α-catenin pathway: a novel efficient protocol for neuronal differentiation. Neurosci Lett. 2015;590:138-144.
49. Rauner M, Franke K, Murray M, et al. Increased EPO Levels Are Associated with Bone Loss in Mice Lacking PHD2 in EPOProducing Cells. J Bone Miner Res. 2016 Apr 15 (Epub ahead of print).
50. Hsu SH, Chen CT, Wei YH. Inhibitory effects of hypoxia on metabolic switch and osteogenic differentiation of human mesenchymal stem cells. Stem Cells. 2013;31(12):2779-2788.
51. Liu T, Zou W, Shi G, Xu J, Zhang F, Xiao J, Wang Y. Hypoxia-induced MTA1 promotes MC3T3 osteoblast growth but suppresses MC3T3 osteoblast differentiation. Eur J Med Res. 2015;20:10.
52. Xu Y, Wang S, Tang C, Chen W. Upregulation of long non-coding RNA HIF 1α-anti-sense 1 induced by transforming growth factor-β-mediated targeting of sirtuin 1 promotes osteoblastic differentiation of human bone marrow stromal cells. Mol Med Rep. 2015;12(5):7233-7238.
53. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci. 2000;920:292-304.